The treatment, given only once, was tested successfully on 55 dogs with cancer and anaemia. It increases muscle strength and counteracts common cancer complications such as weakness, weight loss and anaemia, principal investigator Dr Ruxandra Draghia-Akli, a researcher with VGX Pharmaceuticals Inc. in The Woodlands, Texas, said in a prepared statement.
"With our type of gene therapy, we can trick certain types of cells in the body to naturally produce specific hormones," he said. These hormones have a muscle-building, or anabolic, effect.
In the study 54 percent of the dogs responded to gene therapy, confirmed by blood tests, after three months.
Of those dogs, 84 percent lived longer than those that did not respond to gene therapy and other dogs with cancer that received a placebo.
The dogs who responded had a better quality of life, especially a better appetite, and their complications of chemotherapy, such as vomiting and diarrhoea, were greatly reduced, the study found.
VGX Pharmaceuticals has applied to the US Food and Drug Administration for permission to study this treatment in humans with cancer cachexia, a form of cancer linked to limited food intake, Draghia-Akli said. - (HealthDay News)
Read more:
Human disease insight from dogs
Pet Centre
June 2008